CTLA-4 Antigen

Home
About
Help
History (1)
- CTLA-4 Antigen
- See All Pages

"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.

Descriptor ID	D060908
MeSH Number(s)	D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
Concept/Terms	CTLA-4 Antigen CTLA-4 Antigen Antigen, CTLA-4 CTLA 4 Antigen Antigens, CD152 CD152 Antigens Cytotoxic T-Lymphocyte-Associated Antigen 4 Cytotoxic T Lymphocyte Associated Antigen 4 Cytotoxic T-Lymphocyte Antigen 4 Cytotoxic T Lymphocyte Antigen 4 CD152 Antigen Antigen, CD152

Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
CTLA-4 Antigen [D12.776.543.750.705.222.750]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
CTLA-4 Antigen [D23.050.301.264.894.158]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
CTLA-4 Antigen [D23.101.100.894.158]

Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.

Bar chart showing 59 publications over 24 distinct years, with a maximum of 8 publications in 1998

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	0	4	4
1997	0	6	6
1998	0	8	8
1999	0	7	7
2000	0	5	5
2001	0	4	4
2002	0	3	3
2003	0	1	1
2005	0	3	3
2006	0	1	1
2007	0	1	1
2009	0	2	2
2012	1	0	1
2013	0	1	1
2014	1	0	1
2016	0	1	1
2017	0	2	2
2018	1	0	1
2019	0	2	2
2020	0	1	1
2021	0	1	1
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.

Chen D, Varanasi SK, Hara T, Traina K, Sun M, McDonald B, Farsakoglu Y, Clanton J, Xu S, Garcia-Rivera L, Mann TH, Du V, Chung HK, Xu Z, Tripple V, Casillas E, Ma S, O'Connor C, Yang Q, Zheng Y, Hunter T, Lemke G, Kaech SM. CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity. 2023 09 12; 56(9):2086-2104.e8.

View in: PubMed
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garc?a-Beccaria M, Fern?ndez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenw?lder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discov. 2022 03 01; 12(3):812-835.

View in: PubMed
Zhang H, Wang Z, Zhang J, Gui Z, Han Z, Tao J, Chen H, Sun L, Fei S, Yang H, Tan R, Chandraker A, Gu M. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Front Immunol. 2021; 12:618737.

View in: PubMed
Kethireddy N, Thomas S, Bindal P, Shukla P, Hegde U. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. J Oncol Pharm Pract. 2021 Jan; 27(1):207-211.

View in: PubMed
Furtado VF, Melamud K, Hassan K, Rohatgi S, Buch K. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. Clin Imaging. 2020 Jul; 63:35-49.

View in: PubMed
Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 12; 11(17):1507-1521.

View in: PubMed
Gonzalez-Nieto L, Castro IM, Bischof GF, Shin YC, Ricciardi MJ, Bailey VK, Dang CM, Pedre?o-Lopez N, Magnani DM, Ejima K, Allison DB, Gil HM, Evans DT, Rakasz EG, Lifson JD, Desrosiers RC, Martins MA. Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques. PLoS Pathog. 2019 09; 15(9):e1008015.

View in: PubMed
Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019 07; 95(7):936-939.

View in: PubMed
Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clin Drug Investig. 2019 Jun; 39(6):503-519.

View in: PubMed
Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:13-19.

View in: PubMed

People

Explore

Similar Concepts

Top Journals